Clinical Trial on Alzheimer’s Patients Indicates Positive Safety and Tolerability Data for IGC’s THC-Based Investigational New Drug
Cannabis Law Report
DECEMBER 14, 2021
During the Phase 1 trial, minimal adverse events were reported, and IGC-AD1 was tolerated with no safety concerns identified by an independent Data Safety Monitoring Board. The primary endpoint of our Phase 1 clinical trial was to test and demonstrate safety and tolerability. The average age was 80.9 In addition, 66.7%
Let's personalize your content